Structure Therapeutics (NASDAQ: GPCR) shares Q3 2025 update and results

Rhea-AI Filing Summary

Structure Therapeutics Inc. furnished a current report describing a new press release that provides a corporate update and the company’s financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for those detailed results.

The report clarifies that this information, including Exhibit 99.1, is furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.

false 0001888886 True 0001888886 2025-11-06 2025-11-06 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember 2025-11-06 2025-11-06 0001888886 gpcr:OrdinarySharesParValue0.0001PerShareMember 2025-11-06 2025-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Structure Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Cayman Islands		001-41608		98-1480821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Gateway Blvd., Suite 900 South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code): (650) 457-1978

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Name Of Each Exchange Trading Symbol(s)		On Which Registered
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share		GPCR		Nasdaq Global Market
Ordinary shares, par value $0.0001 per share*		True		Nasdaq Global Market*

* Not for trading, but only in connection with the registration of the American Depositary Shares

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Structure Therapeutics Inc.
Date: November 6, 2025	By:	/s/ Raymond Stevens
		Raymond Stevens, Ph.D.
		Chief Executive Officer

FAQ

What did Structure Therapeutics (GPCR) disclose in this 8-K filing?

Structure Therapeutics furnished an 8-K noting a press release with a corporate update and financial results for the quarter ended September 30, 2025. The full details are contained in Exhibit 99.1, which is incorporated by reference into the report.

Which period’s results are covered in Structure Therapeutics’ latest update?

The update covers Structure Therapeutics’ financial results for the third quarter ended September 30, 2025. These results, along with a broader corporate update, are presented in the press release attached as Exhibit 99.1 to the current report.

How are the Q3 2025 results of Structure Therapeutics provided to investors?

The Q3 2025 results are provided through a press release that accompanies the current report as Exhibit 99.1. Investors must review that exhibit to see specific figures and commentary on the company’s financial performance and corporate update.

Is the Structure Therapeutics Q3 2025 information considered filed with the SEC?

No, the company states the current report and Exhibit 99.1 are furnished, not filed, under the Exchange Act. This distinction affects potential liability and limits automatic incorporation into other SEC registration or reporting documents.

What exhibits are attached to Structure Therapeutics’ November 6, 2025 8-K?

The filing includes Exhibit 99.1, a press release dated November 6, 2025 with the Q3 2025 update, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document, supporting electronic reporting requirements.